{
    "body": "What is the mode of action of everolimus?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17890266", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24183081", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19620795", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20384580", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19299048", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16625599", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16699448", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21279702", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18025810", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22139982"
    ], 
    "ideal_answer": [
        "Everolimus is a drug that binds to mTORC1 and inhibits activation of the mTOR signalling pathway. It is used in targeted cancer therapy protocols or after transplantation for maintenance immunosuppression, against allograft rejection."
    ], 
    "concepts": [
        "http://www.biosemantics.org/jochem#4267185"
    ], 
    "type": "summary", 
    "id": "52f125332059c6d71c000007", 
    "snippets": [
        {
            "offsetInBeginSection": 520, 
            "offsetInEndSection": 575, 
            "text": "Target-of-Rapamycin Inhibitors (Sirolimus, Everolimus),", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22139982", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 161, 
            "offsetInEndSection": 372, 
            "text": "Although the mTOR inhibitor everolimus is effective for the treatment of patients who have failed TKI therapy, it is important to consider all available treatment options before switching therapy mode of action.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21279702", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 323, 
            "offsetInEndSection": 771, 
            "text": "The mTOR pathway, and its upstream regulators in the PI3K/PTEN/AKT cascade, are altered in a variety of experimental and human malignancies.This has led to the prediction that mTOR inhibitors may be used as anticancer agents. With the recent approval of two mTOR-targeted drugs (temsirolimus and everolimus) for the treatment of renal cell carcinoma and mantle cell lymphoma, this paradigm has been effectively translated into the clinical setting.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20384580", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 406, 
            "offsetInEndSection": 811, 
            "text": "mTOR inhibitors such as Temsirolimus (CCI779) and Everolimus (RAD001) are effective for suppressing cell growth with inhibiting mTOR kinase activity. Rapamycin and its related analogs such as Temsirolimus and Everolimus are less toxic for humans compared with other anti-VEGFR inhibitors and has been used as an immunosuppressive agent. These agents have an inhibitory activity against the mTORC1 complex.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19620795", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 763, 
            "offsetInEndSection": 887, 
            "text": "mTOR inhibitors act on the signaling pathway PI3K/AKT/mTOR, and key molecules are temsirolimus, everolimus, and deforolimus.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19299048", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 494, 
            "offsetInEndSection": 690, 
            "text": "The introduction of the inhibitors of the mammalian target of rapamycin sirolimus and everolimus in renal transplantation has increased the repertoire of immunosuppressive protocols substantially.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17890266", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 119, 
            "text": "Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18025810", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 368, 
            "offsetInEndSection": 508, 
            "text": "RAD001 (everolimus) is a novel agent that is being trialled in the treatment of neuro-endocrine tumours, and is known to interact with mTOR.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18025810", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1159, 
            "offsetInEndSection": 1305, 
            "text": "In this cell model, octreotide and RAD001 appear to act through a similar pathway and inhibit the Akt-mTOR-p70S6 kinase pathway downstream of Akt.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18025810", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 57, 
            "text": "Target of rapamycin inhibitors (sirolimus and everolimus)", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16699448", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 64, 
            "text": "Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus)", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16625599", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 131, 
            "text": "Target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus) are immunosuppressive agents with a novel mode of action", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16625599", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 367, 
            "offsetInEndSection": 625, 
            "text": "These three classes are tyrosine kinase inhibitors with sunitinib and sorafenib, the anti-VEGF antibodies (bevacizumab which is associated with alpha interferon in the treatment of advanced kidney cancer) and mTOR inhibitors with temsirolimus and everolimus.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183081", 
            "endSection": "abstract"
        }
    ]
}